Description:

Anti-VEGF therapy has revolutionized the treatment of exudative retinal vascular disease. Whereas the first generations of anti-VEGF therapy hoped to improve quality of life through vision maintenance and remediation, newer advancement hope to decrease the burden of treatment while providing comparable visual outcomes. This course will briefly review current paradigms of anti-VEGF therapy before delving into novel anti-VEGF delivery systems and agents.

Course Code:

AOA344-TD

Speaker(s):

Daniel Epshtein, O.D.

daniel.epshtein.od@gmail.com

Credits:

1

AOA Expiration Date:

12/2/2025

Related News

When to consider referring for low-vision rehabilitation

This Low Vision Awareness Month—and year-round—know when to refer, how to find the right provider and other considerations to help patients maintain their quality of life.

Bringing the optometric community together

The AOA announced its new Advocacy Network Partner Program and recognized Alan Glazier, O.D., the influential founder of ODs on Facebook, as its first advocacy network partner. Read more about the doctor of optometry behind the online community.

Cutting-edge education at Optometry’s Meeting® 2025 in Minneapolis

A global audience converges on the American Heartland for unmatched learning opportunities at Optometry’s Meeting®, June 25-28, in Minneapolis.

Some parts of our website will be briefly unavailable while we perform server maintenance Wednesday, February 19 at 3:30pm central. 

close icon